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ABSTRAK 
 
Pengekspresan terlampau P-glikoprotin (P-gp), hasil bagi gen untuk kaset pengikatan 
ATP (ABC), subfamili B, ahli 1 (ABCB1/MDR1), memain peranan penting dalam mem-
perantarai ketahanan multidrug terhadap dadah antiepilepsi (DAE), pada lebih kurang 
30% daripada pesakit epilepsi. Variasi genetik mungkin merupakan sebahagian dari-
pada sebab kenapa terdapatnya perbezaan inter-individu dalam perhubungan fenotip-
genotip bagi respons farmakologikal pesakit epilepsi terhadap DAE. Sinonim poly-
morfisme C3435T adalah satu daripada varian alel yang paling kerap berlaku pada 
gen ABCB1/MDR1, dan ini  dicadangkan sebagai penyebab epilepsi refraktori. Banyak 
kajian telah menunjukkan hubungan antara polimorfisme C3435T dan refraktori terha-
dap DAE bagi penyakit epilepsi. Walaupun begitu, terdapat kontroversi antara hasil 
penemuan dari pelbagai kajian, iaitu, sama ada  polimorfisme gen ABCB1/MDR1 
C3435T berkait dengan respons terhadap DAE bagi pesakit epilepsi. Kertas ulasan ini 
memberikan latarbelakang dan membincangkan hasil penyiasatan pada faktor-faktor 
yang bercanggah yang mempengaruhi interpretasi dan implementasi kajian-kajian 
asosiasi dalam bidang ini. 
 
Kata kunci:  epilepsi, dadah antiepileptik, ketahanan dadah, respons terhadap dadah, 
ABCB1, P-gp, polimorfisme nukleotid tunggal 
 
 
ABSTRACT  
 
 Over-expression of P-glycoprotein (P-gp), the encoded product of the ATP-binding 
cassette (ABC), sub-family B, member 1 (ABCB1/MDR1) gene, plays an important role 
in mediating multidrug resistance to antiepileptic drugs (AEDs) in about 30% of 
patients with epilepsy. Genetic variation may in part explain inter-individual differences 
in phenotype-genotype relationships in the pharmacological response of epilepsy 
patients to AEDs. The synonymous C3435T polymorphism is one of the most common 
allelic variants in the ABCB1/MDR1 gene, proposed in the causation of refractory 
epilepsy. Many studies have shown the relationship between C3435T polymorphism 
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and refractoriness to AEDs in epilepsy. However, there is controversy between the 
findings of various studies, that is, whether ABCB1/MDR1 C3435T gene polymorphism 
is associated with response to AEDs in epilepsy patients. This review provides a 
background and discusses the results of investigations on possible confounding 
factors affecting the interpretation and implementation of association studies in this 
area. 
 
Key words:  epilepsy, antiepileptic drugs, pharmacoresistance, drug responsiveness, 
ABCB1, P-gp, single nucleotide polymorphism 
 
 
 
INTRODUCTION  
 
Epilepsy is a chronic disorder character-
ized by a predisposition to recurrent un-
provoked seizures. Seizures are caused 
by abnormal neuronal discharges in the 
brain. Despite appropriate pharmaco-
therapy, about one third of newly treated 
epilepsy patients have refractoriness to 
medical treatment (Elger & Schmidt 
2008). The most prominent hypothesis 
for explaining refractoriness to antiepi-
leptic drugs (AEDs) in epilepsy is the 
multidrug-transporter hypothesis, which 
was first explored in chemotherapy-re-
sistant cancer. Excess efflux of AEDs 
across the blood-brain barrier (BBB) 
caused by overexpression of efflux 
transporters suggests that alterations in 
entry and extrusion of drugs into and out 
of cells may be an important mechanism 
of pharmacoresistance (Schmidt & 
Löscher 2005). P-glycoprotein 170 (P-gp) 
is the most studied protein among the 
ATP-binding cassette (ABC) efflux trans-
porters (Schinkel et al. 1994), encoded 
by ABC subfamily B member 1 trans-
porter or multidrug resistance (ABCB1/ 
MDR1) gene. Evidence has shown that 
ABCB1/MDR1 expression was elevated 
in the epileptic foci of drug resistant epi-
lepsy up to ten times indicating its main 
role in pharmacoresistance (Tishler et al. 
1995; Gottesman et al. 2002).  
Different responses to pharmacother-
apy among patients with similar clinical 
phenotypes and taking the same doses 
of medication may be explained, in part, 
by single-nucleotide polymorphisms 
(SNPs) as the most frequent type of ge-
netic variation (Schmidt & Löscher 2005). 
Numerous SNPs have been identified in 
ABCB1/MDR1 gene among which the 
C3435T variant is the most common 
polymorphism (Fung & Gottesman 2009). 
The key question of this review is “is the 
C3435T variant of the ABCB1/MDR1 
gene associated with outcomes of AEDs 
treatment in epilepsy?” The initial phar-
macogenetic study demonstrated an as-
sociation of C3435T polymorphism with 
response to AEDs while the replication of 
this study has been controversial with 
consistent and conflicting studies. Herein, 
the sources of bias in association studies 
for the C3435T variant and refractoriness 
to antiepileptic drug (AED) therapy are 
briefly assessed.  
 
P-gp Structure 
 
P-gp is the first discovered human ABC 
transporter more than 30 years ago in 
drug-resistant ovarian cells obtained from 
Chinese hamsters (Juliano & Ling 1976).  
This protein is the product of the 
ABCB1/MDR1 gene, located at 7q21 and 
containing 28 exons with two transcrip-
tion start sites. It is a phosphorylated and 
glycosylated trans-membrane protein 
consisting of approximately 1280 amino 
acids and with a molecular mass of 
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around 170 kDa. P-gp contains two ho-
mologous halves in which a short linker 
region joining the symmetric sequences 
together (Figure 1). Each half is com-
posed of one trans-membrane domain 
(TMD) containing six α-helix segments 
and one ATP-binding motif or ABC unit 
located at the cytoplasmic site. The two 
ATP-binding domains generate energy 
for interaction of drugs with drug-binding 
sites and for efflux transport function. P-
gp mutations in TMDs 5, 6, 11 and 12 
affect substrate specificity and indicate 
the presence of a drug-binding site in this 
region (Fung & Gottesman 2009). 
 
P-gp function 
 
P-gp functions as a transmembrane ef-
flux pump, by moving drugs from the in-
tracellular to the extracellular domain. It 
may also interact with drug molecules 
trapped within the cell membrane lipid 
bilayer. This protein is expressed in many 
normal tissues such as the liver, gastro-
intestinal tract, kidney, adrenal glands 
and the blood–brain barrier (BBB) 
(Löscher & Potschka 2005a). Anatomic 
localization and ability of P-gp in trans-
porting a broad range of compounds 
suggest that this transporter acts as an 
effective cellular protector against toxic 
xenobiotics, drugs and metabolites that 
are its substrates. It does this by secret-
ing these compounds into the bile, urine 
and intestinal lumen, thereby preventing 
their accumulation in critical organs such 
as the brain. Altered P-gp expression and 
activity may influence an individual's sus-
ceptibility to drugs (Löscher & Potschka 
2005b). P-gp transports a broad spec-
trum of substrates in the plasma mem-
brane ranging in size from 250 to almost 
4000 Da including many classes of drugs 
such as calcium channel blockers, lipid-
lowering statins, opioids, chemothera-
peutic agents, HIV protease inhibitors, 
antibiotics, immunosuppressive agents 
and β-adrenergic antagonists. Most 
AEDs are planar lipophilic agents and 
thus substrates for the P-gp transporter 
(Kwan & Brodie 2005). 
 
ABCB1/MDR1 polymorphisms  
 
Any two unrelated humans have millions 
of genetic differences caused by inser-
tion/deletions or SNPs. SNPs are the 
most abundant form of genetic variation. 
About 0.1% of an individual’s DNA se-
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Figure 1: Schematic diagram of human P-gp showing the 12 transmembrane segments fold together to form 
a three dimensional barrel-structure in the membrane. N-linked phosphrylation and glycosylation sites are 
found in the first extracellular loop. The location of common polymorphisms are shown with small circles 
(arrows) and ATP-binding motifs with gray circles (modified from Tanabe et al. 2001). 
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quences are different among which ap-
proximately 80% is represented by 
SNPs. SNPs may be the causal factor of 
about 40% of the variation of the most 
common diseases and 70% of schizo-
phrenia (Goldstein & Cavalleri 2005). Do 
the ABCB1/MDR1 variants account for 
the inter-individual variability in the phar-
macokinetics and pharmacodynamics of 
drugs? The level of P-gp expression is 
highly variable between different indi-
viduals. Inter-individual variability of P-gp 
activity might affect blood levels and drug 
distribution to the specific target com-
partment. Insufficient or excessive drug 
penetration could cause adverse side 
effects or inactivity of drugs, respectively 
(Löscher & Potschka 2005a). The 
ABCB1/MDR1 gene is highly polymor-
phic. Numerous SNPs have been found 
in the ABCB1/MDR1, the majority of 
which involve noncoding regions thus not 
affecting the P-gp amino acid sequence. 
More than 50 variants reside in the cod-
ing region which can possibly cause al-
tered function (Fung & Gottesman 2009).  
Allele frequency for most of the coding 
region SNPs is less than 8% in different 
ethnic populations with the exception of 3 
SNPs in exons 12 (C1236CT), 21 (G 
2677T/A), and 26 (C3435T) in 
ABCB1/MDR1 gene. Both synonymous 
C1236T and C3435T polymorphisms 
change a GGC codon to GGT (Gly412 
Gly) and ATC to ATT (Ile1145Ile), re-
spectively (Table 1). So, what is the role 
of C3435T polymorphism in pharmacore-
sistance in epilepsy? An original report 
suggested a strong and significant asso-
ciation (P=0.006) between the CC geno-
type at 3435 in ABCB1/MDR1 gene and 
drug-resistant epilepsy (Siddiqui et al. 
2003). Zimprich et al.  (2004) confirmed 
the results of the first report (p = 0.035), 
but Tan et al. (2004a), with the exact 
replication of the first study and almost 
twice the sample size, failed to confirm 
the original findings (Zimprich et al. 2004; 
Tan et al. 2004a). Furthermore, 
Leschziner et al. (2008) in a comprehen-
sive genome wide approach failed to 
confirm the association of C3435T poly-
morphism and response to AEDs 
(Leschziner et al. 2008). In total, 26 
studies attempted to examine this hy-
pothesis in epilepsy, but only 8 found a 
positive association (Table 2). The stud-
ies are divided into two groups: positive 
and negative associations, some of 
which are replications of the initial posi-
tive study (Table 2). It is unclear why 
these reports have found such contra-
dictory results. How can such contradic-
tory results be interpreted? Is there any 
obvious effect of C3435T polymorphism 
on response to AEDs even if the pheno-
types are almost similar? There may be 
several reasons for such discordant 
findings which are discussed below.  
 
Publication bias 
 
Authors and journal editors prefer to pub-
lish papers with positive findings which 
can lead to publication bias. Method-
ologic weaknesses and consequent bias 
or even robust study designs and analy-
ses with significant positive results at the 
5% level in association studies may lead 
to false positive data probably arising by
 
Table 1: Common polymorphisms in ABCB1/MDR1 gene 
 
Exon 
no. 
Ref SNP mRNA 
position 
Wild- type 
allele 
Mutant 
allele 
a.a. 
position 
a.a. 
residue 
a.a. 
change 
Function 
12 Rs1128503 1236 C C 412 Gly Gly Synonymous 
21 Rs2032583 2677 G G 893 Ala Ser Missense 
21 Rs2032583 2677 G G 893 Ala Thr Missense 
26 Rs1045642 3435 C T 1145 Ile Ile Synonymous 
a.a.: amino acid 
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chance (Cardon & Palmer 2003; Tan et 
al. 2004b). The initial positive association 
study between C3435T polymorphism 
and multidrug resistance in epilepsy 
(Siddiqui et al. 2003) is a publication bias 
and may be a false positive result. Hence 
17 subsequent studies could not confirm 
the first finding by improving the statisti-
cal power through increasing sample size 
(Colhoun et al. 2003). To avoid such a 
false positive association report, it is rec-
ommended to publish the original study 
only with α = 0.005 or lower. Even at this 
significance level and 50% power, the 
chance of true positive findings is about 
10%, and so the findings should be inter-
preted with caution. In association stud-
ies between C3435T polymorphism and 
multidrug resistance in epilepsy, most 
authors have pointed to low power due to 
small sample size as a limitation. The 
total sample size in the 26 association 
studies is 7352 (282.77 ± 31.29), ranging 
from 45 to 609 epilepsy cases (Table 2). 
In order to have a power of 80%, these 
studies require a large sample size or 
collaboration between multi-centres and 
countries (Otto 2004).  
 
Definition of drug-responsiveness and 
drug-resistant epilepsy 
 
There have been a number of definitions 
for drug-resistant epilepsy. Selection of 
the most appropriate definition for a par-
ticular study depends on the type of sei-
zure and epilepsy syndrome and the pur-
pose of using the definition. According to 
the National Association of Epilepsy 
Centres (NAEC), pharmacoresistance in 
epilepsy is defined when seizures do not 
come under control after 9 months of 
treatment under the care of a neurologist 
or when a patient does not become sei-
zure-free for 12 months during long-term 
state-of-the-art treatment with several 
suitable AEDs at maximal tolerated 
doses. Surgery, as an alternative to 
pharmacotherapy for about 5–10% of 
newly diagnosed patients can be used to 
define drug resistance because it would 
be assumed that the seizures remained 
uncontrolled after treatment with various 
drugs (Elger 2003; Schmidt & Löscher 
2005). Most association studies for 
C3435T and multidrug resistance epi-
lepsy have divided patients into “drug-
resistant” and “drug-responsive” groups. 
The definition of drug-responsiveness 
and drug-resistance varies amongst 
these studies. In summary, drug-respon-
siveness is defined as complete seizure 
freedom over three months to one year 
and/or more or 50% reduction or more in 
seizure frequency within one year, while 
drug-resistance is defined as having one 
or more seizures per month or four to 10 
or more seizures in six months or one 
year, or less than 50% reduction of sei-
zures per year taking at least two AEDs, 
and also surgery for seizure control (Ta-
ble 2). Additionally, some studies have 
used healthy individuals instead of drug-
responsive patients as controls 
(Kasperaviciute & Sisodiya 2009). Since 
the definition of drug-responsiveness and 
drug-resistance is different between 
studies, patients who are classified as 
drug resistant in some studies may be 
drug-responsive in others. Therefore 
such variation in patients’ classification 
may lead to wrong conclusions. To have 
reliable findings, there need to be an 
agreement on the definition of drug re-
sponsiveness and drug resistance in 
epilepsy.  
  
AED-therapy  
 
a. AEDs–P-gp interactions  
 
There is discrepancy in the transporter 
hypothesis as a mechanism for AED-re-
sistant epilepsy. Some reports suggest 
that P-gp plays a significant role in medi-
ating resistance to AEDs. This includes 
drugs such as phenytoin (PHT), car-
bamazepine (CBZ), phenobarbitone 
69 
 
Med & Health 2009; 4(2): 64-75  Haerian B.S. et al 
 
(PHB), and lamotrigine (LTG) which, as 
P-gp substrates induce upregulation of 
P-gp expression in the brain. However, 
valproic acid (VPA) and vigabatrin do not 
produce the same effects (Sills et al. 
2005). Therefore, based on this hypothe-
sis, in some association studies for 
ABCB1/MDR1 gene polymorphism and 
response to CBZ, VPA or other drugs 
that may not be substrates for P-gp, this 
polymorphism probably may not play any 
role in determining drug resistance 
(Kimura et al. 2007) and the patients, 
classified as drug resistant, may not 
really be pharmacoresistant. However, 
in-vitro observations do not support this 
hypothesis as CBZ, PHT, and VPA 
(Baltes et al. 2007a, Baltes et al. 2007b, 
Rivers et al. 2008), possibly belong to a 
class of “weak substrates” of human P-
gp and may compete for drug-binding 
sites on P-gp and inhibit the transport of 
other substrates (Luna-Tortós et al. 
2008). Determination of which AEDs are 
real substrates of P-gp requires in vivo 
experiments.  
 
b. AED–AED and AED-nonAED 
interactions  
 
In patients who are on multiple drug ther-
apy, drug interactions may occur in which 
one drug may modify the activity of an-
other by enhancing or reducing its phar-
macologic effects with beneficial or 
harmful outcomes. AED–AED or AEDs 
and non-AED interactions in polytherapy 
regimen can significantly influence the 
clinical management in patients with epi-
lepsy, pharmacokinetically and pharma-
codynamically. For example, phenobar-
bitone (PHB), PHT, and CBZ as enzyme 
inducers, can increase the level of activi-
ties of various cytochrome P450 and 
UGT isoenzymes. Therefore, a combina-
tion of PHB, PHT, and CBZ with VPA, 
LTG, topiramate, and tiagabine in poly-
therapy increases and decreases their 
metabolism and half-lives, respectively 
(Patsalos et al. 2002). In association 
studies for C3435T polymorphism and 
refractory epilepsy, some authors have 
not differentiated between monotherapy 
and polytherapy treatments which could 
have influenced the results of their study. 
To prevent such a problem, the possible 
effect of ABCB1/MDR1 polymorphism on 
refractoriness to each AED monotherapy 
must be established. 
 
Haplotype  
 
SNPs are often associated with particular 
variants existing on the same chromo-
some known as a ‘haplotype’ which may 
play a role in response to drugs and dis-
ease susceptibility (Goldstein & Cavalleri 
2005). Such a non-random association of 
SNPs is called linkage disequilibrium 
(LD) (Goldstein & Cavalleri 2005). Some 
reports have demonstrated significant LD 
between synonymous 3435C>T and 
1236C>T and nonsynonymous 
2677G>T/A (Ala893Ser or Ala893Thr), 
suggesting that C3435T and 2677G>T/A 
may influence P-gp function in epilepsy 
patients in response to AEDs (Kim et al. 
2001). In association studies for C3435T 
polymorphism and refractory epilepsy 
with negative results, some authors have 
suggested that since the C3435T variant 
is silent, its effect is possibly caused by 
specific haplotypes (CGC, TGC and TTT) 
of C1236T and G2677T/A (Hung et al. 
2005). It was hypothesized that the pres-
ence of the C3435T variant within a 
haplotype block can affect the timing of 
co-translational folding and P-gp struc-
ture which could influence its insertion 
into the membrane and subsequently 
change the structure of substrate and 
inhibitor interaction sites (Kimchi-Sarfaty 
et al. 2007). Haplotypes may potentially 
improve the statistical power under cer-
tain circumstances. However, the debate 
still exists whether SNPs or haplotypes 
are more appropriate for genetic asso-
ciation studies (Tan et al. 2004b). Finally, 
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many genes including drug-transporters, 
drug-metabolizing enzymes, and drug 
targets are responsible for drug respon-
siveness in epilepsy (Löscher et al. 2008) 
Therefore, one need to investigate the 
entire genetic effect of these genes and 
their SNPs together, rather than study a 
particular variant or haplotype in a single 
gene. 
  
Population heterogeneity 
 
a. Epilepsy types 
 
Epilepsy is heterogenous in nature, influ-
enced by different genes and environ-
ment. Drug resistance differ amongst 
patients with different types of seizures 
and epilepsy syndromes, and the popu-
lation (Duncan et al. 2006). A study on 
Finnish epilepsy cases performed by 
Sillanpää et al. (1999) showed that 
pharmacoresistance to AEDs was seen 
in about 78% of patients with sympto-
matic partial or symptomatic generalised 
epilepsies and 13% of patients with idio-
pathic generalised epilepsies but not in 
patients with idiopathic partial epilepsies 
(Sillanpää et al. 1999). Such a high fre-
quency of drug resistance in sympto-
matic epilepsy (for example structural 
brain lesions) could be caused by over-
expression of P-gp due to the effect of 
frequent seizures or AEDs therapy 
(Löscher 2005c). This will release exci-
totoxic metabolites from the altered tis-
sue and inhibit the efficacy of AEDs for 
treatment, irrespective of the C3434T 
gene polymorphism involvement 
(Schmidt & Löscher 2005). Most asso-
ciation studies for C3434T gene poly-
morphism and refractoriness have been 
conducted on either a specific subset of 
epilepsy types/syndromes or all the vari-
ous types of epilepsies which could 
therefore confound the results. To avoid 
such a bias, the relationship of pharma-
coresistance with C3434T gene poly-
morphism should be separately calcu-
lated for different epilepsy types including 
idiopathic, symptomatic and cryptogenic.  
 
b. Ethnicity effect 
 
The distribution of allele and haplotype 
frequency is different among populations, 
reflected by differing ancestral histories. 
This difference may be caused by re-
sponses to natural selection, migration 
patterns, stochastic effects and founder 
events. Therefore, different ethnic groups 
may have various allele frequencies in 
both disease and non-disease genes 
(Cardon & Palmer 2003). Genotyping of 
the C3435T polymorphism in different 
normal populations have shown that the 
C-variant is more frequent than T-variant 
and is the dominant ancestral allele, car-
ried by more than 74% Africans (Figure 
2) (Ameyaw et al. 2001). The wild 
haplotype (CGC) frequency in South 
American and African populations is 
more than the mutated type (TTT) while 
the opposite is true for the Asians (Fung 
& Gottesman 2009). The prevalence of 
the C-variant in the initial report was 
more in the drug-resistant than the drug-
responsive Caucasian epilepsy patients 
(Siddiqui et al. 2003). However, in most 
of the studies with Asian cases (Seo et 
al. 2006; Kwan et al. 2007; Kim et al. 
2008a, Kim et al. 2008b, Chen et al. 
2007; Lakhan et al. 2009; Vahab et al. 
2009; Szoeke et al. 2009) the opposite 
was seen, which was similar to the nor-
mal population (Figure 2), probably re-
flecting the complex role of C3435T 
polymorphism in the response of AEDs in 
different ethnic populations. In summary, 
based on the C allele and LD differences 
between various epilepsy and normal 
populations, inclusion of patients with 
various ethnicities in the association 
studies for C3435T variant and 
refractoriness in epilepsy can potentially 
introduce heterogeneity which would
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Figure 2: The C3435T allele frequency amongst normal populations with different ethnicities 
 
 
confound the findings (Tan et al. 2004a, 
Shahwan et al. 2007). 
 
CONCLUSION 
 
Despite more than 26 association studies 
in epilepsy involving the common 
ABCB1/MDR1 C3435T variant and re-
fractoriness, 16 of the replicated studies 
failed to confirm the original report. This 
review has provided an opportunity for 
better understanding of the methodologi-
cal problems in these association studies 
by highlighting five sources of bias which 
may confound the results. First, publica-
tion bias which can be caused by false 
positive results, found by chance in the 
initial report as a result of insufficient 
sample size, and low statistical power. 
Second, varying definitions of drug-re-
sponsive and drug-resistant epilepsy in 
the different studies could lead to differ-
ent results. Third, for some AEDs, it is 
not clear whether they are substrates of 
P-gp; hence justification of the results is 
difficult. Moreover, the interaction be-
tween AED–AED and AED-nonAED in 
polytherapy regimen can influence re-
sponse to AEDs. Fourth, certain haplo-
types, formed by C3435T with specific 
variants in ABCB1/MDR1 or other genes 
and SNPs may affect the response to 
AEDs. Finally, the studies may involve a 
heterogeneous population made up of 
combinations of various cases with dif-
ferent epilepsy syndromes or ethnicities. 
In order to obtain reliable results in the 
genetic association studies for C3435T 
polymorphism and refractoriness, these 
factors need to be controlled. 
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